Novartis said its neuromuscular candidate delpacibart etedesiran (del-desiran) failed to meet a primary endpoint in a Phase 3 study (HARBOR, NCT06411288), adding to pressure on the company’s late-stage neuroscience portfolio. The trial missed statistically significant improvement versus placebo on video Hand Opening Time (vHOT) through week 54.